We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02018523
Recruitment Status : Terminated (Study did not enroll enough subjects to make a statistically sound conclusion.)
First Posted : December 23, 2013
Last Update Posted : January 18, 2018
Celgene Corporation
Baylor College of Medicine
Information provided by (Responsible Party):
Jun Zhang, Baylor College of Medicine

Brief Summary:
The purpose of this study is to investigate the safety and efficacy of maintenance therapy with daily low dose lenalidomide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after first line chemotherapy. Investigators expect this treatment approach will delay disease progression by boosting the patient's anti-tumor immune response. Investigators hypothesize that 10 mg/day of lenalidomide can be administered safely as maintenance therapy and improve progression free survival time.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: Lenalidomide Phase 1

Detailed Description:
For patients with stage IIIB/IV non-small cell lung cancer, who did not progress after first line chemotherapy, lenalidomide 10mg/day orally will be administered as maintenance therapy until disease progression or death.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy
Study Start Date : June 2014
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Lenalidomide
Oral lenalidomide 10 mg daily until disease progression
Drug: Lenalidomide
lenalidomide 10mg/day orally until disease progression
Other Name: Revlimid

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: up to 6 months from the date of registration ]
    Progression free survival is defined as the duration of time from the date starting lenalidomide to the date of documented radiographic progression or death.

Secondary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: From date of registration to end of study, up to 3 years ]
  2. Change in circulating immune cells [ Time Frame: Change from baseline at 1 week ]
  3. Change in circulating immune cells [ Time Frame: Change from baseline at 5 weeks ]
  4. Change in circulating immune cells [ Time Frame: Change from baseline at 9 weeks ]
  5. Change in circulating immune cells [ Time Frame: Change from baseline at 13, 17, 21 and 25 weeks ]
  6. Change in circulating immune cells [ Time Frame: Change from baseline to 6 months, 9 months and 1 year ]
  7. Change in circulating immune cells [ Time Frame: Change from baseline to 1.5, 2, 2.5 and 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed stage IIIB or stage IV NSCLC with measurable disease at initial presentation prior to chemotherapy. See Section 8.4.1 for measurable disease parameters.
  • Patients must have had a complete response (CR), partial response (PR) or stable disease (SD) after 4-6 cycles of first-line chemotherapy. Tumor response will be assessed by RECIST criteria version 1.1.
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, or radiotherapy before entering this study.

    1. Myelosuppressive chemotherapy: At least 21 days elapsed from end of treatment before registration (42 days if prior nitrosourea).
    2. Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor.
    3. Other: For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
    4. XRT: > or = to 2 weeks for local palliative XRT (small port); 3 months must have elapsed if 50% radiation of pelvis; 6 weeks must have elapsed if other substantial bone marrow radiation.
  • Patients must be > or = 18 years of age.
  • ECOG performance status < or = to 1 (Karnofsky > 70%).
  • Organ Functions: Patients must have normal organ and marrow function as defined below within 28 days of registration:

    1. Leukocytes > or = 3,000/uL
    2. Absolute neutrophil count > or = 1,500/uL
    3. Hemoglobin > or = 8 g/dL
    4. Platelets > or = 100,000/uL
    5. Total bilirubin 1.5X institutional upper limit of normal (ULN)
    6. AST (SGOT) and ALT (SGPT) 1.5X institutional ULN
    7. Creatinine clearance > or = 60 mL/min/1.73 m2 for patients with creatinine levels > institutional normal
  • All study participants must be willing and agree to be registered into the mandatory REVLIMID REMS program, and be willing and able to comply with the requirements of REVLIMID REM. REVLIMID REMS registration does not need to be complete to determine study eligibility.
  • Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days before registration. Treating investigator must affirm intention to perform another serum or urine UPT 24 hours before initiating lenalidomide treatment.

    *FCBP: A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

  • All patients must be counseled about pregnancy precautions, risks of fetal exposure and other risks. The counseling must be done before the initiation of the study and every 28 days before the study drug is dispensed to the subject. FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix D: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.
  • Able to take aspirin (81 mg) daily as prophylactic anticoagulation (Patients intolerant to ASA may use warfarin or low molecular weight heparin).
  • Able to understand and willing to sign a written informed consent document.
  • Life expectancy > or = 12 weeks

Exclusion Criteria

  • Concomitant Medications:

    1. Patients may not be receiving any other anti-cancer therapy.
    2. Patients may not be receiving any other investigational agents.
    3. Patients may not be receiving systemic steroids or other immunosuppressive drugs; however, steroid containing inhaler may be allowed after discussing with the Principal Investigator. Duration of 5 half-lives must have elapsed before the study registration if the patient was on systemic steroids or other immunosuppressive drugs.
  • Patients with untreated brain metastasis, or with treated brain metastasis but requiring steroids.
  • Patients with known EGFR mutation or EML-ALK fusion gene and with stage IV disease.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide or thalidomide.
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, autoimmune disease or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breastfeeding women are excluded from this study because lenalidomide has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenalidomide, breastfeeding should be discontinued if the mother is treated with lenalidomide.
  • Known sera-positive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
  • Any other clinically significant medical condition and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02018523

Layout table for location information
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Jun Zhang
Celgene Corporation
Baylor College of Medicine
Layout table for investigator information
Principal Investigator: Jun Zhang, M.D. Baylor College of Medicine

Layout table for additonal information
Responsible Party: Jun Zhang, Assistant Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT02018523    
Other Study ID Numbers: H-32774
First Posted: December 23, 2013    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018
Keywords provided by Jun Zhang, Baylor College of Medicine:
Carcinoma, Non-Small-Cell Lung
Stage 3B/4
Maintenance Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents